Moleculin Announces Positive Interim Data in Annamycin MB-106 Phase 1B/2 AML Trial

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/1/2026

1. MDT
2. ENOV
3. BLSM
4. AON
5. AZN
6. GRMN
7. PTGX
8. AAPL
9. LTGO
10. KRMN

Go back to Moleculin Announces Positive Interim Data in Annamycin MB-106 Phase 1B/2 AML Trial
METABASIS THERAPEUT (NASDAQ: MBRX) Delayed: 0.64 --0 (-0%)
Previous Close $0.64    52 Week High $9.58 
Open $0.64    52 Week Low $2.34 
Day High $0.64    P/E N/A 
Day Low $0.64    EPS $-0.34 
Volume 1,763